Skip to search formSkip to main contentSkip to account menu

M-2 protocol

Known as: BCNU/CTX/L-PAM/PRED/VCR, Carmustine/Cyclophosphamide/Melphalan/Prednisone/Vincristine, VBMCP 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Antineoplastic Combined Chemotherapy ProtocolsCarmustineCyclophosphamide
MelphalanPrednisoneVincristine

Narrower (1)

VBMCP protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Clinical and biological implication of defective p53 pathway in multiple myeloma (MM).
17516 Background: The p53 tumor suppressor is commonly inactivated by mutations. Even in tumors without mutations, there are… 
2004
2004
New Therapeutic Approaches to Myeloma
Effective treatment for myeloma began in the early 1960s with the introduction of melphalan and cyclophosphamide (1). During the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)